Lantern Pharma (LTRN) Cash from Operations (2019 - 2026)

Lantern Pharma (LTRN) has reported Cash from Operations for 8 consecutive years, with -$2.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations rose 25.31% year-over-year to -$2.9 million; the trailing twelve-month figure through Jun 2026 stood at -$14.1 million (up 21.21% YoY), and the FY2025 full-year result was -$15.7 million, up 11.99% from the prior year.
• Cash from Operations rose to -$2.9 million in Q2 2026 per LTRN's latest filing, from -$3.8 million in the prior quarter.
• Across five years, Cash from Operations topped out at -$2.7 million in Q4 2022 and bottomed at -$5.6 million in Q3 2024.
• Historically, Cash from Operations has averaged -$3.7 million across 5 years, with a median of -$3.7 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Cash from Operations tumbled 58.37% in 2022, then climbed 29.7% in 2025.
• Over 5 years, Cash from Operations stood at -$2.7 million in 2022, then decreased by 26.85% to -$3.4 million in 2023, then slipped by 17.32% to -$4.0 million in 2024, then gained by 29.7% to -$2.8 million in 2025, then decreased by 5.33% to -$2.9 million in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered -$2.9 million, -$3.8 million, and -$2.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.